Diving into the Debate Surrounding Aducanumab for Alzheimer’s

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Peter Whitehouse, MD, PhD The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.